Idorsia Urges DEA to Deschedule Chronic Insomnia Drug Class

Title: Idorsia Appeals for DEA to Deschedule Chronic Insomnia Drug Class: An Effort to Address a Widespread Sleep Disorder


Chronic Insomnia affects millions of people around the world, leading to significant physical and mental health consequences. The search for effective treatments has been ongoing, and Idorsia, a pharmaceutical company, is now urging the Drug Enforcement Administration (DEA) to deschedule the drug class used for treating chronic insomnia. In this blog post, we will highlight the key points surrounding this appeal, the impact it could have on patients, and the importance of addressing this widespread sleep disorder appropriately.

Key Points:

  1. The Burden of Chronic Insomnia:
    Chronic insomnia is a sleep disorder characterized by difficulty falling asleep, staying asleep, or experiencing non-restorative sleep for at least three nights per week, persisting for at least three months. It can significantly impact an individual’s quality of life, leading to fatigue, impaired cognitive function, mood disturbances, and decreased productivity.
  2. Idorsia’s Appeal to Deschedule Drug Class:
    Idorsia is urging the DEA to deschedule the drug class used for treating chronic insomnia. Currently, some medications used for insomnia treatment fall under Schedule IV or Schedule V classification according to the Controlled Substances Act. Descheduling would allow for easier access to these drugs, potentially benefiting patients suffering from chronic insomnia.
  3. Improved Patient Access to Treatment:
    Descheduling the drug class for chronic insomnia could improve patient access to appropriate medication. Rather than being classified as controlled substances, these medications may become more readily available, reducing obstacles for patients seeking treatment. Increased access to effective medications can positively impact the management of chronic insomnia and overall patient well-being.
  4. Addressing the Stigma Associated with Insomnia:
    Descheduling the drug class for chronic insomnia may also help reduce the stigma surrounding the disorder. Currently, the association of some insomnia medications with controlled substances can inadvertently contribute to the perception that chronic insomnia is merely a matter of poor sleep hygiene or willpower. By destigmatizing the treatment options, individuals with chronic insomnia can receive the understanding and support they need.
  5. Balancing Safety and Regulation:
    While the appeal for descheduling focuses on improving patient access, it is crucial to consider the need for balanced safety measures and regulation. The appropriate use and potential side effects of medications should not be underestimated. Striking a balance between patient access and ensuring responsible use is essential to protect individuals’ well-being while addressing the challenge of chronic insomnia.
  6. Ongoing Research and Treatment Advancements:
    The appeal to deschedule the drug class for chronic insomnia underscores the need for continued research and advancements in treating this sleep disorder. Insomnia is a complex condition influenced by various factors, and evolving treatment options can lead to better outcomes for patients. The appeal serves as a reminder of the ongoing efforts to improve the lives of individuals affected by chronic insomnia.


Idorsia’s appeal to the DEA to deschedule the drug class for chronic insomnia highlights the significance of addressing this widespread sleep disorder. By potentially improving patient access, reducing stigma, and promoting appropriate management, descheduling could have a positive impact on individuals suffering from chronic insomnia. However, it is crucial to find a balance between easing access and ensuring safety and regulation. As research and treatment advancements continue, addressing chronic insomnia as a legitimate health concern will become increasingly important, leading to better outcomes and support for those affected by this challenging condition.